Reference : B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery...
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/110131
B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia
English
Kerns, H. M. [> >]
Ryu, B. Y. [> >]
Stirling, B. V. [> >]
Sather, B. D. [> >]
Astrakhan, A. [> >]
Humblet, Stéphanie [Université de Liège - ULg > > GIGA-R : Hématologie >]
Liggitt, D. [> >]
Rawlings, D. J. [> >]
2010
Blood
American Society of Hematology
115
11
2146-55
Yes (verified by ORBi)
International
0006-4971
1528-0020
Washington
DC
[en] The immunodeficiency disorder, X-linked agammaglobulinemia (XLA), results from mutations in the gene encoding Bruton tyrosine kinase (Btk). Btk is required for pre-B cell clonal expansion and B-cell antigen receptor signaling. XLA patients lack mature B cells and immunoglobulin and experience recurrent bacterial infections only partially mitigated by life-long antibody replacement therapy. In pursuit of definitive therapy for XLA, we tested ex vivo gene therapy using a lentiviral vector (LV) containing the immunoglobulin enhancer (Eµ) and IgB (B29) minimal promoter to drive B lineage-specific human Btk expression in Btk/Teck-/- mice, a strain that reproduces the features of human XLA. After transplantation of EµB29-Btk-LV-transduced stem cells, treated mice showed significant, albeit incomplete, rescue of mature B cells in the bone marrow, peripheral blood, spleen, and peritoneal cavity, and improved responses to T-independent and T-dependent antigens. LV-teated B cells exhibited enhanced B-cell antigen receptor signaling and an in vivo selective advantage in the peripheral versus central B-cell compartment. Secondary transplantation showed sustained Btk expression, viral integration, and partial functional responses, consistent with long-term stem cell marking; and serial transplantation revealed no evidence for cellular or systemic toxicity. These findings strongly support pursuit of B lineage-targeted LV gene therapy in human XLA.
http://hdl.handle.net/2268/110131

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Humblet-Blood 2146-2010.pdfPublisher postprint1.45 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.